CyDex awarded additional Captisol patent
The US PTO has granted CyDex new patent for the production of ultra high-purity modified cyclodextrin.
The patent, number 7,635,773, covers a manufacturing process for producing the compounds, including CyDex’ beta cyclodextrin sulfobutyl ether sodium salt product solubilisation Captisol
CEO Theron Odlaug said that: “Together with the morphology patent we received [in December], this patent ultimately provides broader protection for our clients using Captisol and provides them with critical life-cycle management for their products.”
At present Capsitol is used to aid delivery in five US Food and Drug Administration (FDA) approved pharmaceuticals made by Pfizer, Bristol-Myers Squibb (B-MS) and Prism Pharmaceuticals.
